Biolife Solutions Inc Stock
Price
Target price
€26.20
€26.20
0.770%
0.2
0.770%
-
28.07.26 / Stuttgart Stock Exchange
WKN: A1XCF2 / Name: BioLife / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Biolife Solutions Inc Stock
Biolife Solutions Inc gained 0.770% compared to yesterday.
Pros and Cons of Biolife Solutions Inc in the next few years
Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Biolife Solutions Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biolife Solutions Inc | 0.770% | 2.344% | 4.800% | 37.895% | 24.762% | 47.191% | -33.469% |
| Pacira Pharmaceuticals | -1.720% | 1.786% | 2.703% | 21.925% | 5.556% | -30.061% | -53.659% |
| Supernus Pharmaceuticals | 3.000% | -1.905% | 0.000% | 44.056% | -4.186% | 49.275% | 82.301% |
| Collegium Pharmaceutical Inc | -0.640% | -1.274% | 3.333% | 16.541% | -25.121% | 56.566% | 50.485% |
News
Repligen Q2 Earnings Call Highlights
Key Points
- Interested in Repligen Corporation? Here are five stocks we like better.
- Strong second-quarter performance: Repligen reported $204 million in revenue, up 12% year over year and 13%
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
Key Points
- Interested in Repligen Corporation? Here are five stocks we like better.
- Repligen is acquiring BioLife Solutions in a deal valued at about $1.5 billion, paying $31 per share in a